Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $651000.0.

  • BioLineRx's Net Cash Flow rose 17500.0% to $651000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 24266.79%. This contributed to the annual value of $6.2 million for FY2024, which is 20083.5% up from last year.
  • Per BioLineRx's latest filing, its Net Cash Flow stood at $651000.0 for Q3 2025, which was up 17500.0% from -$2.3 million recorded in Q2 2025.
  • BioLineRx's Net Cash Flow's 5-year high stood at $3.9 million during Q2 2024, with a 5-year trough of -$3.7 million in Q4 2023.
  • For the 3-year period, BioLineRx's Net Cash Flow averaged around -$263181.8, with its median value being -$868000.0 (2024).
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 21834.15% in 2024, then crashed by 17826.6% in 2025.
  • Over the past 3 years, BioLineRx's Net Cash Flow (Quarter) stood at -$3.7 million in 2023, then surged by 139.25% to $1.4 million in 2024, then crashed by 54.73% to $651000.0 in 2025.
  • Its Net Cash Flow was $651000.0 in Q3 2025, compared to -$2.3 million in Q2 2025 and -$1.3 million in Q1 2025.